Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic – a randomised, double-blinded, placebo-controlled study
In: Beneficial MicrobesDepartment of Child Health Care, Chengdu New Century Women’s and Children’s Hospital, No.77, Baojia Lane, Qingyang District, Chengdu, China P.R.
Search for other papers by K. Chen in
Current site
Google Scholar
Search for other papers by G. Zhang in
Current site
Google Scholar
Search for other papers by H. Xie in
Current site
Google Scholar
Search for other papers by L. You in
Current site
Google Scholar
Search for other papers by H. Li in
Current site
Google Scholar
Search for other papers by Y. Zhang in
Current site
Google Scholar
Search for other papers by C. Du in
Current site
Google Scholar
Search for other papers by S. Xu in
Current site
Google Scholar
Search for other papers by C. Melsaether in
Current site
Google Scholar
Search for other papers by S. Yuan in
Current site
Google Scholar
To evaluate the administration of Bifidobacterium animalis subsp. lactis, BB-12® (BB-12) on infant colic in breastfed infants, a double-blind, placebo-controlled randomised study was conducted in Chengdu, China from April 2016 to October 2017 with 192 full-term infants less than 3 months of age and meeting the ROME III criteria for infant colic. After a 1-week run-in the infants were randomly assigned to receive daily BB-12 (1×109 cfu/day) or placebo for 3 weeks. Crying/fussing time were recorded using a 24 h structured diary. The primary endpoint was the proportion of infants achieving a reduction in crying and fussing time of ≥50% from baseline. Parent’s/caregiver’s health related quality of life was measured using a modified PedsQL™ 2.0 Family Impact Module and immunological biomarkers were evaluated from faecal samples at baseline and after the 21-day intervention. The percentage of infants achieving a reduction in the daily crying/fussing time ≥50% after the 21-day intervention was significantly higher in the infants supplemented with BB-12 (P<0.001). The mean number of crying episodes was significantly reduced in the BB-12 group compared to the placebo group (10.0±3.0 to 5.0±1.87 vs 10.5±2.6 to 7.5±2.8, respectively) (P<0.001) and the mean daily sleep duration was markedly increased from baseline to end of intervention in the BB-12 group compared to the infants in the placebo group (60.7±104.0 vs 31.9±102.7 min/day, respectively) (P<0.001). The faecal levels of human beta defensin 2, cathelicidin, slgA, calprotectin and butyrate were statistically higher in the BB-12 group compared to the placebo group after the 21-day intervention. At the end of the intervention the parent’s/caregiver’s physical, emotional and social functioning scores were significantly higher for the BB-12 group compared to the placebo group (all P<0.05). Supplementation of BB-12 is effective in reducing crying and fussing in infants diagnosed with infant colic.
-
Adlerberth, I. and Wold, A.E., 2009. Establishment of the gut microbiota in Western infants. Acta Paediatrica 98: 229-238. https://doi.org/10.1111/j.1651-2227.2008.01060.x
-
Bekkeali, N., Hamers, S.L., Reitsma, J.B., Van Toledo, L. and Benninga, B., 2009. Infant stool form scale: development and results. Journal of Pediatrics 154: 521-526. https://doi.org/10.1016/j.jpeds.2008.10.010
-
Benninga, M.A., Nurko, S., Faure, C., Hyman, P.E., Roberts, I.J. and Schetcher, N.L., 2016. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 150: 1443-1455. https://doi.org/10.1053/j.gastro.2016.02.016
-
Canani, R.B., Costanzo, M.D., Leone, L., Pedata, M., Meli, R. and Calignano, A., 2011. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology 17: 1519-1528. https://doi.org/10.3748/wjg.v17.i12.1519
-
DeWeerth, C., Fuentes, S., Puylaert, P. and De Vos, W.M., 2013. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 131: e550-558. https://doi.org/10.1542/peds.2012-1449
-
Dryl, R. and Szajewska, H., 2018. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Archives of Medical Science 14: 1137-1143. https://doi.org/10.5114/aoms.2017.66055
-
Fujiwara, T., Barr, R.G., Brandt, R. and Barr, M., 2011. Infant distress at five weeks of age and caregiver frustration. Journal of Pediatrics 159: 425-430. https://doi.org/10.1016/j.jpeds.2011.02.010
-
Gensollen, T., Iyer, S.S., Kasper, D.L. and Blumberg, R.S., 2016. How colonization by microbiota in early life shapes the immune system. Science 352: 539-544. https://doi.org/10.1126/science.aad9378
-
Grzeskowiak, L., Collado, M.C., Mangani, C., Maleta, K., Laitinen, K., Ashorn, P., Isolauri, E. and Salminen, S., 2012. Distinct gut microbiota in southeastern African and northern European infants. Journal of Pediatric Gastroenterology and Nutrition 54: 812-816. https://doi.org/10.1097/MPG.0b013e318249039c
-
Gupta, S., 2002. Is colic a gastrointestinal disorder? Current Opinion in Pediatrics 14: 588-592. https://doi.org/10.1097/00008480-200210000-00005
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews: Gastroenterology and Hepatology 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
-
Hyman, P.E., Milla, P.J., Benninga, M.A., Davidson, G.P., Fleisher, D.F. and Taminiau, J., 2006. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 130: 1519-1526. https://doi.org/10.1053/j.gastro.2005.11.065
-
Kapel, N., Campeotto, F., Kalach, N., Baldassare, M., Butel, M.J. and Dupont, C., 2010. Faecal calprotectin in term and preterm neonates. Journal of Pediatric Gastroenterology and Nutrition 51: 542-547. https://doi.org/10.1097/MPG.0b013e3181e2ad72
-
Li, F., Ma, J., Geng, S., Wang, J., Liu, J., Zhang, J. and Sheng, X., 2015. Fecal calprotectin concentrations in healthy children aged 1-18 months. PLoS ONE 10: e0119574. https://doi.org/10.1371/journal.pone.0119574
-
Lu, C.Y. and Ni, Y.H., 2015. Gut microbiota and the development of pediatric diseases. Journal of Gastroenterology 50: 720-726. https://doi.org/10.1007/s00535-015-1082-z
-
Mohan, R., Koebnick, C., Schildt, J., Schmidt, S., Mueller, M., Possner, M., Radke, M. and Blaut, M., 2006. Effects of Bifidobacterium lactis BB12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. Journal of Clinical Microbiology 44: 4025-4031. https://doi.org/10.1128/JCM.00767-06
-
Nocerino, R., Filippis, F.D., Cecere, G., Marino, A., Micillo, M., Di, C., Caro, C.D., Calignano, A., Bruno, C., Paparo, L., Iannicelli, A.M., Cosenza, L., Maddalena, Y., Gatta, G., Coppola, S., Carucci, L., Ercolini, D. and Canani, R.B., 2020. The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: a randomised, double blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics 51: 110-120. https://doi.org/10.1111/apt.15561
-
Ong, T.G., Gordon, M., Banks, S.S.C., Thomas, M.R. and Akobeng, A.K., 2019. Probiotics to prevent infantile colic. Cochrane Database of Systematic Reviews 3: CD012473. https://doi.org/10.1002/14651858.CD012473.pub2
-
Pärtty, A., Kalliomäki, M., Endo, A., Salminen, S. and Isolauri, E., 2012. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS ONE 7: e32495. https://doi.org/10.1371/journal.pone.0032495
-
Savino, F., Cordisco, L., Tarasco, V., Calabrese, R., Palumeri, E. and Matteuzzi, D., 2009. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatrica 98: 1582-1588. https://doi.org/10.1111/j.1651-2227.2009.01419.x
-
Savino, F., Cresi, F., Pautasso, S., Palumeri, E., Tullio, V., Roana, J., Silvestro, L. and Oggero, O., 2004. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatrica 93: 825-829. https://doi.org/10.1111/j.1651-2227.2004.tb03025.x
-
Sung, V., Cabana, M.D., D’Amico, F., Deshpande, G., Dupont, C., Indrio, F., Mentula, S., Partty, A., Savino, F., Szajewska, H. and Tancredi, D., 2014. Lactobacillus reuteri DSM 17938 for managing infant colic: protocol for an individual participant data meta-analysis. BMJ Open 4: e006475. https://doi.org/10.1136/bmjopen-2014-006475
-
Sung, V., D’Amico, F., Cabana, M.D., Chau, K., Koren, G., Savino, F., Szajewska, H., Deshpande, G., Dupont, C., Indrio, F., Mentula, S., Partty, A. and Tancredi, D., 2018. Lactobacillus reuteri to treat infant colic: a meta-analysis. Pediatrics 141: e20171811. https://doi.org/10.1542/peds.2017-1811
-
Varni, J.W., Sherman, S.A., Burwinkle, T.M., Dickinson, P.E. and Dixon, P., 2004. The PedsQL™ family impact module: preliminary reliability and validity. Health and Quality of Life Outcomes 2: 55. https://doi.org/10.1186/1477-7525-2-55
-
Wessel, M.A., Cobb, J.C., Jackson, E.B., Harris, G.S. and Detwiler, A.C., 1954. Paroxysmal fussing in infancy, sometimes called ‘colic’. Peadiatrics 14: 421-435.
'Paroxysmal fussing in infancy, sometimes called ‘colic’ ' () 14 Peadiatrics : 421 -435.
-
Willers, M., Ulas, T., Völlger, L., Vogl, T., Heinemann, A.S., Pirr, S., Pagel, J., Fehlhaber, B., Halle, O., Schöning, J., Schreek, S., Löber, U., Essex, M., Hombach, P., Graspeuntner, S., Basic, M., Bleich, A., Cloppenborg-Schmidt, K., Künzel, S., Jonigk, D., Rupp, J., Hansen, G., Förster, R., Baines, J.F., Härtel, C., Schultze, J.L., Forslund, S.K., Roth, J. and Viemann, D., 2020. S100A8 and S100A9 are important for postnatal development of gut microbiota and immune system in mice and infants. Gastroenterology 159: 2130-2145. https://doi.org/10.1053/j.gastro.2020.08.019
-
Wolke, D., Bilgin, A. and Samara, M., 2017. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. Journal of Pediatrics 185: 55-61.e54. https://doi.org/10.1016/j.jpeds.2017.02.020
-
Xinias, I., Analitis, A., Mavroudi, A., Roilides, I., Lykogeorgou, M., Delivoria, V., Milingos, V., Mylonopoulou, M. and Vandenplas, Y., 2017. Innovative dietary intervention answers to baby colic. Pediatric Gastroenterology, Hepatology and Nutrition 20: 100-106. https://doi.org/10.5223/pghn.2017.20.2.100
-
Zeevenhooven, J., Browne, P.D., L’Hoir, M.P., De Weerth, C. and Benninga, M.A., 2018. Infant colic: mechanisms and management. Nature Reviews Gastroenterology and Hepatology 15: 479-496. https://doi.org/10.1038/s41575-018-0008-7
Supplementary Materials
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 1120 | 975 | 195 |
| PDF Views & Downloads | 1684 | 1521 | 196 |
Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic – a randomised, double-blinded, placebo-controlled study
In: Beneficial MicrobesDepartment of Child Health Care, Chengdu New Century Women’s and Children’s Hospital, No.77, Baojia Lane, Qingyang District, Chengdu, China P.R.
Search for other papers by K. Chen in
Current site
Google Scholar
PubMed
Search for other papers by G. Zhang in
Current site
Google Scholar
PubMed
Search for other papers by H. Xie in
Current site
Google Scholar
PubMed
Search for other papers by L. You in
Current site
Google Scholar
PubMed
Search for other papers by H. Li in
Current site
Google Scholar
PubMed
Search for other papers by Y. Zhang in
Current site
Google Scholar
PubMed
Search for other papers by C. Du in
Current site
Google Scholar
PubMed
Search for other papers by S. Xu in
Current site
Google Scholar
PubMed
Search for other papers by C. Melsaether in
Current site
Google Scholar
PubMed
Search for other papers by S. Yuan in
Current site
Google Scholar
PubMed
To evaluate the administration of Bifidobacterium animalis subsp. lactis, BB-12® (BB-12) on infant colic in breastfed infants, a double-blind, placebo-controlled randomised study was conducted in Chengdu, China from April 2016 to October 2017 with 192 full-term infants less than 3 months of age and meeting the ROME III criteria for infant colic. After a 1-week run-in the infants were randomly assigned to receive daily BB-12 (1×109 cfu/day) or placebo for 3 weeks. Crying/fussing time were recorded using a 24 h structured diary. The primary endpoint was the proportion of infants achieving a reduction in crying and fussing time of ≥50% from baseline. Parent’s/caregiver’s health related quality of life was measured using a modified PedsQL™ 2.0 Family Impact Module and immunological biomarkers were evaluated from faecal samples at baseline and after the 21-day intervention. The percentage of infants achieving a reduction in the daily crying/fussing time ≥50% after the 21-day intervention was significantly higher in the infants supplemented with BB-12 (P<0.001). The mean number of crying episodes was significantly reduced in the BB-12 group compared to the placebo group (10.0±3.0 to 5.0±1.87 vs 10.5±2.6 to 7.5±2.8, respectively) (P<0.001) and the mean daily sleep duration was markedly increased from baseline to end of intervention in the BB-12 group compared to the infants in the placebo group (60.7±104.0 vs 31.9±102.7 min/day, respectively) (P<0.001). The faecal levels of human beta defensin 2, cathelicidin, slgA, calprotectin and butyrate were statistically higher in the BB-12 group compared to the placebo group after the 21-day intervention. At the end of the intervention the parent’s/caregiver’s physical, emotional and social functioning scores were significantly higher for the BB-12 group compared to the placebo group (all P<0.05). Supplementation of BB-12 is effective in reducing crying and fussing in infants diagnosed with infant colic.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 1120 | 975 | 195 |
| PDF Views & Downloads | 1684 | 1521 | 196 |